Ovid Therapeutics Inc. (OVID)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 80M 160M 240M Q3 '21: 214.1M Q4 '21: 208.4M Q1 '22: 1.4M Q2 '22: 1.4M Q3 '22: 1.5M Q4 '22: 1.5M Q1 '23: 123.4K Q2 '23: 198.4K Q3 '23: 296.3K Q4 '23: 392K Q1 '24: 474K Q2 '24: 568K Q3 '24: 632K Q4 '24: 566K Q1 '25: 548K Q2 '25: 6.7M Q3 '25: 6.6M Q4 '25: 7.3M Q1 '26: 7.1M Q2 '26: 1.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-100M -50M 0 50M 100M 150M Q3 '21: 129M Q4 '21: 124.2M Q1 '22: -68.6M Q2 '22: -68.6M Q3 '22: -69.7M Q4 '22: -55.5M Q1 '23: -54.2M Q2 '23: -54M Q3 '23: -53.3M Q4 '23: -59.3M Q1 '24: -61.8M Q2 '24: -68.2M Q3 '24: -69.3M Q4 '24: -61.9M Q1 '25: -57M Q2 '25: -41.6M Q3 '25: -40.9M Q4 '25: -42.4M Q1 '26: -47.7M Q2 '26: -58.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-100M -50M 0 50M 100M 150M Q3 '21: 126.8M Q4 '21: 122.8M Q1 '22: -69.3M Q2 '22: -68.1M Q3 '22: -68.7M Q4 '22: -54.2M Q1 '23: -51.4M Q2 '23: -49.2M Q3 '23: -48.5M Q4 '23: -52.3M Q1 '24: -50.7M Q2 '24: -29.7M Q3 '24: -32.5M Q4 '24: -26.4M Q1 '25: -25M Q2 '25: -38.2M Q3 '25: -36.3M Q4 '25: -17.4M Q1 '26: -24.2M Q2 '26: -34.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-100M -50M 0 50M 100M 150M Q3 '21: 116.1M Q4 '21: 118.6M Q1 '22: -62.4M Q2 '22: -56.2M Q3 '22: -58M Q4 '22: -55.2M Q1 '23: -47.3M Q2 '23: -45.7M Q3 '23: -43M Q4 '23: -45.8M Q1 '24: -50.4M Q2 '24: -52.9M Q3 '24: -57.9M Q4 '24: -56M Q1 '25: -49.5M Q2 '25: -40.1M Q3 '25: -37.9M Q4 '25: -38.3M Q1 '26: -42M Q2 '26: -54.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-100M -50M 0 50M 100M 150M Q1 '21: 127.6M Q2 '21: 125.4M Q3 '21: 116M Q4 '21: 118.4M Q1 '22: -62.6M Q2 '22: -57.5M Q3 '22: -59.3M Q4 '22: -56.5M Q1 '23: -48.4M Q2 '23: -45.8M Q3 '23: -43.2M Q4 '23: -45.8M Q1 '24: -50.4M Q2 '24: -53M Q3 '24: -57.9M Q4 '24: -56M Q1 '25: -49.6M Q2 '25: -40.1M Q3 '25: -38M Q4 '25: -38.3M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '20: 54.7M Q2 '20: 55.6M Q3 '20: 59.4M Q1 '21: 66.6M Q2 '21: 67.8M Q3 '21: 67.9M Q1 '22: 70.3M Q2 '22: 70.4M Q3 '22: 70.4M Q1 '23: 70.5M Q2 '23: 70.5M Q3 '23: 70.6M Q1 '24: 70.7M Q2 '24: 71.2M Q3 '24: 71M Q1 '20 Q3 '20 Q2 '21 Q1 '22 Q3 '22 Q2 '23 Q1 '24 Q3 '24

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q4 '19: -1.58 Q1 '20: -1.49 Q2 '20: -1.56 Q3 '20: -1.41 Q4 '20: -1.41 Q1 '21: 1.49 Q2 '21: 1.67 Q3 '21: 1.78 Q4 '21: 1.76 Q1 '22: -1.00 Q2 '22: -0.98 Q3 '22: -0.98 Q4 '22: -0.77 Q1 '23: -0.73 Q2 '23: -0.70 Q3 '23: -0.69 Q4 '23: -0.75 Q1 '24: -0.73 Q2 '24: -0.43 Q3 '24: -0.47 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.